High-Intensity Focused Ultrasound (HIFU) Focal Therapy for Localized Prostate Cancer with MRI-US Fusion Platform

Chi‐Hang Yee, Peter Ka‐Fung Chiu, Jeremy Yuen‐Chun Teoh, Chi‐Fai Ng, Chi‐Kwok Chan, See‐Ming HouAdvances 2021 · DOI

TL;DR

This study investigates the efficacy of MRI-US fusion platforms in guiding High-Intensity Focused Ultrasound (HIFU) focal therapy for localized prostate cancer. The findings suggest that while the fusion platform offers a trend towards longer operative times, both conventional and fusion-guided HIFU deliver comparable oncological and functional outcomes, indicating that current fusion technology may not offer a significant advantage over established methods for this specific application.

What Problem Does This Paper Address?

Prostate cancer treatment has seen a shift towards focal therapies, aiming to balance effective cancer control with minimized side effects. High-Intensity Focused Ultrasound (HIFU) is one such focal therapy. However, precisely targeting the cancerous lesion during HIFU has been a challenge. Traditionally, HIFU relied on transrectal ultrasound (TRUS) for guidance, which can be limited in its ability to accurately pinpoint lesions identified on multiparametric MRI (mpMRI). The advent of MRI-US fusion platforms promised to bridge this gap by integrating MRI-derived lesion information into the real-time ultrasound guidance, potentially improving localization accuracy and treatment precision. This paper addresses the question of whether this advanced fusion technology actually leads to improved outcomes compared to conventional HIFU guidance.

Methods

This was a prospective observational study involving 20 patients with localized prostate cancer undergoing HIFU focal therapy. The study design involved a comparison between two groups: the first 10 patients received conventional HIFU focal therapy guided by TRUS alone, while the subsequent 10 patients were treated using an MRI-US fusion platform.

Key methodological aspects include:

  • Patient Selection: Strict inclusion criteria were applied, including clinical tumor stage ≤T2, visible index lesion on mpMRI (<20 mm diameter), absence of Gleason 5 pattern on biopsy, and PSA ≤20 ng/ml.
  • HIFU Procedure: HIFU was performed using the Sonablate® 500 device. Treatment was delivered in a focal lesion or quadrant fashion. The MRI-US fusion platform (Sonafuse™™™-MIM Symphony™™™) was used for lesion localization in the latter half of the study, integrating pre-installed MRI images and contouring of the gland and index lesions. The study notes a limitation of "rigid fusion" rather than "elastic fusion."
  • Outcome Measures:
    • Primary Outcome: Treatment failure rate, defined by the need for salvage therapy.
  • Secondary Outcomes: Tumor recurrence on follow-up biopsy, PSA changes, perioperative complications, and postoperative functional outcomes (assessed via IPSS, OABSS, IIEF-5, SF-12, EPIC-26, and uroflowmetry).
  • Follow-up: Patients underwent mpMRI at 1 week and 6 months post-treatment. Routine follow-up biopsy was arranged at 6 months. PSA, functional assessments, and uroflowmetry were checked at 3 and 6 months.
  • Statistical Analysis: Standard statistical tests like t-tests, ANOVA, and linear regression were employed, with a p-value <0.05 considered significant.

Datasets

Not discussed in the paper. The study utilized patient data collected prospectively during the treatment period.

Key Insights and Ideas

  • Fusion Platform Trend: The MRI-US fusion platform showed a trend towards longer total operative times (124.2 min vs. 107.1 min, p=0.066) compared to conventional HIFU. This suggests that the planning and fusion process adds extra time to the procedure.
  • No Significant Difference in Ablation Precision: Despite the advanced guidance, there was no statistically significant difference in the mean ablation volume to lesion volume ratio between the fusion and conventional groups. This implies that the fusion technology, in its current rigid form, did not necessarily lead to more precise focal ablation.
  • PSA Drop Similarities: While the conventional group showed a more significant mean PSA percentage change from baseline to 6 months (63.3% vs. 44.6%, p=0.035), this was noted as a secondary outcome and the overall oncological outcomes were deemed similar.
  • Energy Correlation: Energy used per ablation volume was positively correlated with the patient's PSA density (r=0.6364, p=0.014). This suggests that higher PSA density might require more energy for effective ablation, potentially due to differences in tissue characteristics.
  • Similar Oncological and Functional Outcomes: The most crucial finding is that both conventional and MRI-US fusion HIFU platforms provided similar oncological and functional outcomes. This challenges the assumption that fusion technology inherently leads to superior results in this context.

Key Results

  • Operative Time: Fusion group: 124.2 ± 16.9 min; Conventional group: 107.1 ± 28.3 min (p=0.066).
  • PSA Percentage Change (6-month): Conventional group showed a more significant drop (63.3%) compared to the fusion group (44.6%) (p=0.035).
  • Recurrence: Two patients (one from each group) eventually required radical treatment due to clinically significant prostate cancer recurrence. No in-field recurrences were observed at 6-month mpMRI.
  • Functional Outcomes: No significant differences were observed in uroflowmetry, SF-12 scores, or EPIC-26 scores between the groups.
  • Complications: No significant difference in complications was noted.

Limitations and Future Work

  • Study Size: The study included only 20 patients, which is a relatively small sample size.
  • Follow-up Biopsy Compliance: Only 60% of patients underwent the planned 12-month follow-up biopsy, limiting the completeness of histological assessment.
  • Lack of Randomization: The study was a prospective observational case series, not a randomized controlled trial, which limits definitive causal conclusions regarding the superiority of one method over the other.
  • Rigid Fusion: The MRI-US fusion platform used had "rigid fusion," which may not be as accurate as "elastic fusion" for complex anatomical registrations.
  • Future Work: The authors suggest that future randomized controlled trials are warranted to definitively investigate the treatment outcomes of the fusion HIFU platform. Further evaluation is needed to confirm the benefits of MRI-US fusion HIFU treatment, particularly concerning potential advantages like reduced urine leak observed in other studies.

Summary updated

Abstract

In conclusion, HIFU with conventional or MRI-US fusion platform provided similar oncological and functional outcomes.
BibTeX
@inproceedings{yee2021high,
  author = {Chi‐Hang Yee and Peter Ka‐Fung Chiu and Jeremy Yuen‐Chun Teoh and Chi‐Fai Ng and Chi‐Kwok Chan and See‐Ming Hou},
  title = {{High-Intensity Focused Ultrasound (HIFU) Focal Therapy for Localized Prostate Cancer with MRI-US Fusion Platform}},
  booktitle = {Advances},
  year = {2021},
  doi = {10.1155/2021/7157973},
}

Loading related content...

Figure